Moderna's full pipeline may fuel long-term growth.
The company has had its ups -- the approval of its respiratory syncytial virus (RSV) vaccine back in 2024 -- and its downs -- ...
Zacks Investment Research on MSN
Moderna (MRNA) falls more steeply than broader market: What investors need to know
Moderna (MRNA) ended the recent trading session at $49.56, demonstrating a -7.49% change from the preceding day's closing ...
They aren't just "pandemic stocks." ...
A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The ...
Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct ...
In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk ...
Moderna is working to build a seasonal vaccines portfolio to spur growth. The FDA this week said it won’t review the biotech’s flu vaccine candidate. 10 stocks we like better than Moderna › A few ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results